Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 8/20 | 0.49 |
| ▸ | AVPR1B | P47901 | 8/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.49 |
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | CBX7 | O95931 | 1/20 | 0.44 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7076240 | 0.92 | AVPR1B (0.47) | OXTRAVPR1BAVPR1ABRD4CBX7 | |
| SCHEMBL4590690 | 0.91 | OXTR (0.51) | OXTRAVPR1BAVPR1ABRD4CBX7 | |
| SCHEMBL2495322 | 0.88 | BRD4 (0.46) | OXTRAVPR1BAVPR1ABRD4 | |
| SCHEMBL4590188 | 0.87 | OXTR (0.49) | OXTRAVPR1BAVPR1ABRD4CBX7 | |
| SCHEMBL4590281 | 0.86 | AVPR1B (0.56) | OXTRAVPR1BAVPR1ABRD4CBX7 | |
| SCHEMBL4590704 | 0.86 | AVPR1B (0.58) | OXTRAVPR1BAVPR1ABRD4CBX7 | |
| SCHEMBL2499968 | 0.86 | BRD4 (0.49) | OXTRAVPR1BAVPR1ABRD4MDM2 | |
| SCHEMBL2492934 | 0.86 | AVPR1A (0.53) | OXTRAVPR1BAVPR1ABRD4CBX7 | |
| SCHEMBL2495591 | 0.84 | OXTR (0.50) | OXTRAVPR1BAVPR1ABRD4AVPR2 | |
| SCHEMBL2494928 | 0.84 | AVPR1B (0.56) | OXTRAVPR1BAVPR1ABRD4CBX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| EP-1296976-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sanofi-Aventis (FR) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098295-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-12-27 | — | — | WO | disclosed |
| US-5739149-A | TREATING ASTHMA | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | disclosed |
| US-5635509-A | ASTHMA; BRONCHODILATOR AGENTS; VASODILATION MICROVASCULAR PERMEABILITY; MAST CELLS | ZENECA LIMITED (GB) | 1997-06-03 | — | — | US | disclosed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | OXTR 12/4885AVPR1B 1/4885AVPR1A 2/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | OXTR 9/4885AVPR1B 1/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.